FORT WASHINGTON, PA, USA (Press Release) - November 9, 2009 - Patients with kidney cancer traditionally have not had many treatment choices. Surgery and/or difficult to tolerate immunotherapy was all that was available. In addition, because few early symptoms are visible, patients are often diagnosed late with advanced disease. With the FDA approvals of new agents for renal cell carcinoma, a paradigm shift has occurred in the way patients with renal cell carcinomas are treated. In the past two years, patients have gained access to treatments that have been shown to be effective in tumor reduction with fewer side effects than previous cytokine regimens.

The NCCN Clinical Practice Guidelines in Oncology™ Kidney Cancer provides sequential recommendations for the management of renal cell carcinomas. This webinar will discuss recent, significant updates to the NCCN Guidelines for Kidney Cancer including comparison of new data with existing standards of care, involved patient subsets, and risk-benefit analysis in the diagnosis and treatment of the disease as well as a review of the significant studies that supported modification of the NCCN Guidelines Panels’ recommendations.

Webinar Schedule:

Register Now for one of the following sessions:

• Monday, November 9, 12:00 PM EST
• Tuesday, November 10, 3:00 PM EST
• Wednesday, November 11, 1:00 PM EST
• Thursday, November 12, 6:00 PM EST

Following this program, participants should be able to:

• Describe recent advances in the management of patients with kidney cancer;
• Outline the implications of recent research and practice changes to the clinical algorithms for patients with kidney cancer.

Presenter

Robert A. Figlin, MD
City of Hope Comprehensive Cancer Center

Intended Audience

This program is designed to meet the needs of Physicians, Nurses, Industry, and Other Health Care Professionals who are interested in learning more on the recent updates to the NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer.

Accreditation

Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Faculty Disclosure

All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's and ANCC's Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME's Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2 and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Contributors

Supported by educational grants from Novartis Oncology, Pfizer Inc., Wyeth. Registration Information

There is no fee for this educational webinar. If cancellation is necessary, please notify NCCN. A substitute attendee may be registered in your place.

National Comprehensive Cancer Network

[ PRESS RELEASE ]

Please log-in or register in order to submit comments.

Powered by AkoComment!